Literature DB >> 15577659

CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use.

Fernando Dronda1, Javier Zamora, Santiago Moreno, Ana Moreno, José L Casado, Alfonso Muriel, María J Pérez-Elías, Antonio Antela, Leonor Moreno, Carmen Quereda.   

Abstract

We evaluated the impact of HIV risk practice on immune reconstitution in a prospective cohort of 288 patients (176 former injecting drug users) who maintained complete virus suppression for more than 24 months. Significant differences in CD4 cell counts at 6 and 24 months were detected. Multivariate analysis showed that drug use was an independent predictor of poor immunological recovery. Injection drug abuse impairs short and long-term CD4 cell recovery in HIV-positive patients initiating successful highly active antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15577659     DOI: 10.1097/00002030-200411050-00018

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

1.  HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines.

Authors:  Nazira El-Hage; Guanghan Wu; Juan Wang; Jayakrishna Ambati; Pamela E Knapp; Janelle L Reed; Annadora J Bruce-Keller; Kurt F Hauser
Journal:  Glia       Date:  2006-01-15       Impact factor: 7.452

2.  Management of Hepatitis C in HIV-infected Patients.

Authors:  Benigno Rodriguez; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

3.  Do HIV disease progression and HAART response vary among injecting drug users in Europe?

Authors:  Liselotte van Asten; Robert Zangerle; Ildefonso Hernández Aguado; Faroudy Boufassa; Barbara Broers; Raymond P Brettle; J Roy Robertson; Jim McMenamin; Roel A Coutinho; Maria Prins
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

4.  Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis.

Authors:  Cassidy W Claassen; Marie Diener-West; Shruti H Mehta; David L Thomas; Gregory D Kirk
Journal:  Clin Infect Dis       Date:  2012-03-28       Impact factor: 9.079

Review 5.  Molecular targets of opiate drug abuse in neuroAIDS.

Authors:  K F Hauser; N El-Hage; S Buch; J R Berger; W R Tyor; A Nath; A J Bruce-Keller; P E Knapp
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

6.  Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD).

Authors:  Sam Egger; Kathy Petoumenos; Adeeba Kamarulzaman; Jennifer Hoy; Somnuek Sungkanuparph; John Chuah; Kathleen Falster; Jialun Zhou; Matthew G Law
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-15       Impact factor: 3.731

7.  HIV-1 gp120 primes lymphocytes for opioid-induced, beta-arrestin 2-dependent apoptosis.

Authors:  Jonathan Moorman; Yi Zhang; Bindong Liu; Gene LeSage; Yangchao Chen; Charles Stuart; Deborah Prayther; Deling Yin
Journal:  Biochim Biophys Acta       Date:  2009-05-27

8.  Interactive Effects of Morphine on HIV Infection: Role in HIV-Associated Neurocognitive Disorder.

Authors:  Pichili Vijaya Bhaskar Reddy; Sudheesh Pilakka-Kanthikeel; Shailendra K Saxena; Zainulabedin Saiyed; Madhavan P N Nair
Journal:  AIDS Res Treat       Date:  2012-05-20

9.  Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response.

Authors:  Vlada V Melekhin; Bryan E Shepherd; Samuel E Stinnette; Peter F Rebeiro; Gema Barkanic; Stephen P Raffanti; Timothy R Sterling
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

10.  Outcomes of antiretroviral therapy in Vietnam: results from a national evaluation.

Authors:  Duc Bui Nguyen; Nhan Thi Do; Ray W Shiraishi; Yen Ngoc Le; Quang Hong Tran; Hai Huu Nguyen; Nicholas Medland; Long Thanh Nguyen; Bruce Baird Struminger
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.